Peer-influenced content. Sources you trust. No registration required. This is HCN.

MedPage TodayHow Durable are Responses to Novel Antidepressant Zuranolone in MDD?

In the phase III trial for zuranolone, 67.4% of patients who received an initial 2-week course at the 30-mg dose level initially achieved a 50% or greater reduction from baseline on the HAMD-17. Over the following year, half of those patients required additional 2-week courses of therapy. Of the group who received the 50-mg dose, only 25% needed subsequent courses.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form